Matteo Sclafani, Chiara Perrotti, Luigi Salerno, Melwyn Luis Muthukkattil, Camilla Lustri, Gabriele Cristofari, Giulio Falasconi, Maria Beatrice Musumeci, Diego Penela, Andrea Saglietto, Agnese Iannaccone, Emanuele Barbato, Antonio Berruezo, Pietro Francia
{"title":"肥厚性心肌病的心肌瘢痕成像:CMR和CT的进展。","authors":"Matteo Sclafani, Chiara Perrotti, Luigi Salerno, Melwyn Luis Muthukkattil, Camilla Lustri, Gabriele Cristofari, Giulio Falasconi, Maria Beatrice Musumeci, Diego Penela, Andrea Saglietto, Agnese Iannaccone, Emanuele Barbato, Antonio Berruezo, Pietro Francia","doi":"10.3389/fcvm.2025.1649728","DOIUrl":null,"url":null,"abstract":"<p><p>Myocardial scarring is a hallmark of hypertrophic cardiomyopathy (HCM) and a major driver of adverse outcomes, including sudden cardiac death and heart failure progression. The fibrotic substrate in HCM is complex, encompassing both replacement and interstitial fibrosis, often accompanied by myocardial disarray. Advanced cardiovascular imaging enables detailed scar characterization, which is crucial for risk stratification and personalized management. Cardiovascular magnetic resonance (CMR) is the gold standard for non-invasive fibrosis assessment. Techniques such as late gadolinium enhancement, myocardial mapping of T1 and T2 relaxation properties, and diffusion tensor imaging provide complementary insights into scar burden and architecture. Cardiac computed tomography (CT) is an emerging modality with increasing clinical relevance. Delayed iodine enhancement and CT-derived extracellular volume mapping offer a valuable alternative for scar assessment, particularly when CMR is contraindicated. This review highlights the role of multimodality imaging in assessing myocardial scar in HCM, with a focus on CMR and CT, and explores their clinical implications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1649728"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488738/pdf/","citationCount":"0","resultStr":"{\"title\":\"Imaging myocardial scar in hypertrophic cardiomyopathy: advances in CMR and CT.\",\"authors\":\"Matteo Sclafani, Chiara Perrotti, Luigi Salerno, Melwyn Luis Muthukkattil, Camilla Lustri, Gabriele Cristofari, Giulio Falasconi, Maria Beatrice Musumeci, Diego Penela, Andrea Saglietto, Agnese Iannaccone, Emanuele Barbato, Antonio Berruezo, Pietro Francia\",\"doi\":\"10.3389/fcvm.2025.1649728\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Myocardial scarring is a hallmark of hypertrophic cardiomyopathy (HCM) and a major driver of adverse outcomes, including sudden cardiac death and heart failure progression. The fibrotic substrate in HCM is complex, encompassing both replacement and interstitial fibrosis, often accompanied by myocardial disarray. Advanced cardiovascular imaging enables detailed scar characterization, which is crucial for risk stratification and personalized management. Cardiovascular magnetic resonance (CMR) is the gold standard for non-invasive fibrosis assessment. Techniques such as late gadolinium enhancement, myocardial mapping of T1 and T2 relaxation properties, and diffusion tensor imaging provide complementary insights into scar burden and architecture. Cardiac computed tomography (CT) is an emerging modality with increasing clinical relevance. Delayed iodine enhancement and CT-derived extracellular volume mapping offer a valuable alternative for scar assessment, particularly when CMR is contraindicated. This review highlights the role of multimodality imaging in assessing myocardial scar in HCM, with a focus on CMR and CT, and explores their clinical implications.</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":\"12 \",\"pages\":\"1649728\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488738/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2025.1649728\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1649728","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Imaging myocardial scar in hypertrophic cardiomyopathy: advances in CMR and CT.
Myocardial scarring is a hallmark of hypertrophic cardiomyopathy (HCM) and a major driver of adverse outcomes, including sudden cardiac death and heart failure progression. The fibrotic substrate in HCM is complex, encompassing both replacement and interstitial fibrosis, often accompanied by myocardial disarray. Advanced cardiovascular imaging enables detailed scar characterization, which is crucial for risk stratification and personalized management. Cardiovascular magnetic resonance (CMR) is the gold standard for non-invasive fibrosis assessment. Techniques such as late gadolinium enhancement, myocardial mapping of T1 and T2 relaxation properties, and diffusion tensor imaging provide complementary insights into scar burden and architecture. Cardiac computed tomography (CT) is an emerging modality with increasing clinical relevance. Delayed iodine enhancement and CT-derived extracellular volume mapping offer a valuable alternative for scar assessment, particularly when CMR is contraindicated. This review highlights the role of multimodality imaging in assessing myocardial scar in HCM, with a focus on CMR and CT, and explores their clinical implications.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.